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The role of leucine-47 in determining the structure and activity of human epidermal growth factor was examined using site-directed mutagenesis. 
Wild type protein and four variants in which Leti’ was replaced by valine, glutamate, aspartate and alanine were produced from yeast. ‘H NMR 
experiments demonstrated that substitution of I.&’ had little effect on the protein structure.. The observed reduction in receptor binding affinity 
caused by the substitutions could thus be attributed to perturbation of a residue directly involved in receptor interactions. 
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1. INTRODUCTION 
The 53 amino acid protein epidermal growth factor 
(EGF) is a powerful mitogen for certain cell lines [l]. 
It elicits its response by binding to the EGF receptor, an 
integral membrane protein with intrinsic tyrosine 
kinase activity [2]. Other proteins which are known to 
bind to and activate the EGF receptor include transfor- 
ming growth factor alpha (TGFcu) [3] and several pox- 
virus growth factors [4-61. 
Although there is considerable variation in the se- 
quences of EGFs and TGFas, their three-dimensional 
structures are quite similar [7], and they display similar 
affinities for the EGF receptor [8,9]. Consideration of 
the sequences and structures of EGF and TGFcv enabl- 
ed us to postulate that tyrosine 13, leucine 15, histidine 
16, arginine 41, glutamine 43 and leucine 47 might be 
residues important for interactions with the receptor 
[7]. This led to a site directed mutagenesis project in 
our laboratories to test this hypothesis. The aim was to 
combine receptor binding studies and high resolution 
NMR so that a distinction could be made between a 
mutation causing minor local changes in structure and 
one causing widespread structu@ disruption. 
The importance of leucine 47 (leucine 48 in TGFa) 
for receptor binding has been demonstrated by several 
groups [IO-121. In no case, however, has it been shown 
that the overall structure of the protein was unaffected 
by the mutation. The present study investigates in more 
detail the role of leucine 47 in determining the structure 
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and receptor binding affinity of human EGF (hEGF). 
The wild type form of hEGF(l-52) and four variants 
in which leucine 47 is replaced have been produced 
from yeast using the alpha factor secretion pathway 
[ 131. After purification the receptor binding affinity of 
each was determined and their structural integrity 
assessed by high-resolution nuclear magnetic resonance 
(NMR). The results suggest hat reductions in activity 
associated with substitutions at leucine 47 are not caus- 
ed by widespread structural changes and thus involve a 
residue required for direct interaction with the 
receptor. 
2. MATERIALS AND METHODS 
2.1. E. coli and yeast strains 
E. coli strains MC1061, JM103 and RZ1032 were used for plasmid 
manipulations and site directed mutagenesis. Sacchuromyces 
cerevisiae strain MDSOa/a leu2-3/leu2-3 leu2-112/leu2-112 
pep4-3/ + his3-1 l/his3-11 his3-15/his3-15 was used for protein ex- 
pression. 
2.2. Plasmids 
The plasmid pSP4&F/EGF contains as a EgfII-BamHI restriction 
fragment a synthetic hEGF gene joined to the yeast LY factor leader, 
so that the codon for the first amino acid of EGF immediately 
follows the codons for the lysine-arginine cleavage site of the yeast 
KEX2 protease. The pLFl-cuF/EGF expression vector (fig.1) was 
created by ligating this Bg/II-BumHI fragment into the BgnI expres- 
sion site of pLF1, a derivative of pMA91 [14] in which the ampicillin 
resistance gene of pBR322 is substituted for the gene from pSP46 
which lacks the PsrI site. 
2.3. Mutagenesis 
Site directed mutagenesis was performed on a M13mp19 clone con- 
taining the PstI-BumHI fragment of pSP46_cuF/EGF and a single 
20-mer primer with a degenerate mismatch at the position correspon- 
ding to leucine 47. The degeneracy in the sequence allowed the 
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Fig.1. (A) A reversed phase HPLC trace of purified hBGF(l-52) 
using a Vydac (4.6 x 150 mm) Cl8 wide pore column. Buffer A = 
0.1% trifluoroacetic acid in HrO. Buffer B = 0.1% trifluoroacetic 
acid in acetonitrile. The gradient ran from 20% B to 50% B in 
25 min, at 1 ml/min, after being held at 20% for 5 min. 1Opg of 
sample was injected after 1 min and the absorbance was measured at 
280 nm. (B) SDS-PAGE, 0.5 pg of wild type and the 4 mutants of 
hEGF were loaded in tracks B-F; the molecular masses of some 
marker proteins are indicated in track A; the staining was with 
Coomassie blue. 
substitution of leucine for alanine, valine, aspartic acid, glutamic 
acid and glycine. Sequencing of 17 plaques resulted in the isolation 
of all these mutants except glycine. The PstI-Sac1 fragments were 
then cloned back into pLFl-cuF/EGF to produce pTD508, pTD509, 
pTD5 10 and pTD5 11 which produce the glutamic acid, valine, aspar- 
tic acid and alanine mutants respectively. 
2.4. Culture conditions and EGF purification 
Yeast transformants, which had been produced using a previously 
described protocol [15], were grown selectively in media containing 
per litre: 6.7 g nitrogen base w/o amino acid (Difco) and 10 g 
glucose, supplemented with selected amino acids. After 2-3 daysof 
growth at 30°C in a rotary incubator the cultures were harvested and 
the EGF purified from cell free broth by reversed phase and ion ex- 
change HPLC. Typically between 2 and 4 mg EGF was produced per 
litre of culture. 
2.5. Radioreceptor assay 
The ability of each purified protein to inhibit the binding of “‘1 
labelled murine EGF (Amersham) was measured using a monkey 
Vero cell line. The protein concentration was determined spec- 
trophotometrically using &s& = 2.89/cm (which was calculated by 
summing the contributions of the tyrosine and tryptophan residues). 
2.6. NMR 
Samples for NMR studies were prepared by dissolving pure protein 
in DzO (99.8% pure). After lyophilisation the protein was resuspend- 
ed in DzO and the pH adjusted, where necessary, with NaOD and 
DC1 to pH 2.85-2.95 (uncorrected meter readings). NMR spectra 
were acquired at 303 K using a Bruker AM600 MHz spectrometer. 
One-dimensional spectra were collected in the pulsed Fourier mode 
with 400 transients per spectrum, and with pre-irradiation of the 
residual solvent resonance. 
3. RESULTS AND DISCUSSION 
Human EGF and the four leucine 47 mutants were 
secreted with relatively high efficiency using the yeast 
alpha factor secretion pathway. Purified hEGF was at 
least 95% pure as determined by reversed phase HPLC 
and SDS-PAGE (fig.2). Characterisation by amino 
acid sequencing and fast atom bombardment mass 
spectrometry (data not shown) showed clean N- 
terminal cleavage by the KEX2 protease of the alpha 
factor secretion pathway. The protein was found to be 
missing the C-terminal arginine 53, consistent with 
earlier results which show that this residue is removed 
by a yeast protease [16]. However, the l-52 form of 
EGF is found in vivo [ 171 and has similar activity to the 
l-53 form [9]. 
NMR was used to investigate the effect of the amino 
acid substitutions on the structure of the protein. Hav- 
ing already assigned the spectra of the l-48 and l-53 
forms of hEGF [18,19], it was relatively easy to identify 
spectral features characteristic of ‘correctly folded’ 
hEGF. The downfield regions of one-dimensional spec- 
tra of hEGF and the four mutants are shown in fig.3 
and assignments of several resonances are indicated. 
The structural integrity of each mutant may be 
assessed from the shifts experienced by resonances. As 
is evident from fig.3 and other parts of the spectrum 
(not shown) similar patterns of shifts are observed for 
resonances in the mutant and wild type spectra, sug- 
gesting little perturbation to the folding of the protein. 
This is further suggested by similar patterns of nuclear 
Overhauser effects (NOES) which are also characteristic 
of the folding of the protein. Backbone amide protons 
which are slow to exchange with solvent deuterons have 
been assigned to secondary structural features of hEGF 
[ 18,191. Since the same amide protons are slowly ex- 
changing in each protein (fig.3), similar networks of 
hydrogen bonds and secondary structure are indicated. 
As well as structural information, qualitative details 
of dynamic behaviour are available from the NMR 
spectra. The fact that resonances corresponding to 
hydrogen bonded protons are observed indicates 
similar lifetimes for the hydrogen bonds and thus a 
similar degree of flexibility for each protein. More 
localised information can be obtained from the obser- 
vation that the 3,5H doublet of tyrosine 29 is broaden- 
ed; this can be attributed to a ring current interaction 
with tyrosine 22 and partially restricted motion of the 
tyrosine 29 ring. This broadening is observed in all 
spectra suggesting similar mobilities for this region in 
each protein. 
These observations indicate that there is no major 
change in conformational or dynamic features of the 
leucine 47 mutants. Some features of the spectra of the 
mutants, however, differ from that of the wild type. 
Most differences can be directly related to the substitu- 
tions, for example the spectrum of the alanine mutant 
shows the appearance of a new doublet at 1.39 ppm 
which may be assigned to the,& CH3 of the new alanine. 
Two-dimensional spectra (not shown) were used to find 
the new resonances of residue 47 of the other mutants, 
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Fig.2. The downfield regions of one-dimensional NMR spectra of 
hEGF(l-52) and the four leucine 47 mutants. The resonances of 
slowly exchanging amide protons are marked on the top spectrum, as 
are some of the aromatic resonances of tyrosine 29, tryptophan 49 
and tryptophan 50. 
as well as to confirm the disappearance of resonances 
of leucine 47. Other changes are observed for the 
residues following leucine 47, in particular the 
resonances of tryptophans 49 and 50 can be seen to 
shift in fig.3. Additionally, the shifts of the methyl 
resonances of valine 35 vary slightly between the dif- 
ferent proteins. These resonances are subject to a large 
ring current shift from tryptophans 49 and 50 (R.M. 
Cooke et al., manuscript in preparation). Thus some 
alteration in the packing of the tryptophans with valine 
35 is suggested. It should be stressed, however, that 
residues after Ieucine 47 have been shown to be unim- 
portant for receptor binding 191, and so any structural 
changes in this region are not likely to affect receptor 
binding. 
Receptor binding studies show that the leucine 47 
mutants have reduced binding affinity as seen by their 
reduced ability to compete with lzriI labelled murine 
EGF (which is indicated by their higher ICSO values 
shown in fig.4). Changing leucine 47 to a valine results 
in around a seven-fold increase in the I& whereas 
changes to alanine, aspartic acid or glutamic acid all 
result in around a further seven-fold increase in I&. 
Similar results are seen with human A431 cell line, 
though with more scatter of the data. These activities 
are broadly consistent with the data of others [lo-121 
L47A 
L47D 
Fig.3. The radioreceptor assay of hEGF(l-52) and the four leucine 
47 mutants on monkey Vero cell line. The relative amount of “‘I 
labelled murine EGF which was able to bind is plotted against the 
concentration of each protein. Lines were fitted to the data following 
the function, F= ((A - D)/[l + (X/c)“])+D, which gives the ICSO 
from parameter C [20]. (Parameter A was set to lOO%.) Inset: ICJO 
values obtained from the data. 
which show a reduction in activity on substituting the 
residue corresponding to leucine 47 for another amino 
acid. For each mutant there is a strong correlation bet- 
ween the decrease in receptor binding and the decrease 
in mitogenic activity on a human fibroblast cell line 
(data not shown). 
Thus, since no significant structural changes are 
detected on substituting leucine 47, the considerable 
reduction in receptor binding affinity on changing this 
amino acid even to valine strongly suggests that leucine 
47 is involved in a highly specific contact with the 
receptor. Larger changes than that caused by valine 
result from the presence of alanine, glutamate or aspar- 
tate. This suggests that leucine 47 participates in a 
hydrophobic interaction with the receptor. The 
substitutions of valine and alanine possibly result in 
progressive diminution of the Van der Waals interac- 
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Fig.4. Plasmid map of pLFl-cuF/EGF. Amp = ampicillin resistance gene; ori = E. coli origin of replication; Tet = tetracycline resistance gene 
(Amp-ori-Tet region from pBR322); pPGK = yeast phosphoglycerate kinase promoter; tPGK = yeast phosphoglycerate kinase terminator. 
ting surface, while the introduction of a negative charge 
with glutamate or aspartate possibly destabilises the 
hydrophobic environment. 
In conclusion it has been shown, by a combination of 
mutagenesis, binding assay and NMR techniques, that 
leucine 47 of hEGF is at the interface between the 
growth factor and its receptor. Although minimal 
structural perturbation was detected in the leucine 47 
mutants, we have recently carried out preliminary 
NMR studies on other EGF mutants and have, in one 
case, observed significant spectral perturbations. This 
suggests that reductions in activity can sometimes be 
accompanied by significant changes in protein struc- 
ture. Using NMR to distinguish between local and 
global structural changes, thus promises to be a useful 
additional tool in mapping the surface involved in 
growth factor-receptor interactions. 
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